Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25

Benzinga · 2d ago
Evercore ISI Group analyst Cory Kasimov maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $22 to $25.